Relative to healthy subjects in the prior Phase 1 trial (Supplementary Material), ME/CFS patients were objectively more sensitive to the hemodynamic effects of CRFR2 stimulation during treatment. Here, CRHR2 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.